CSIRO says it welcomes public discussion about the ethics of Artificial Intelligence (AI) following the release of 'Artificial Intelligence: Australia’s Ethics Framework'.
The discussion paper, developed by CSIRO’s Data61, is designed to encourage a conversation on how Australia will develop and uses AI.
"It identifies key governance principles and measures that can be used to achieve the best possible results from AI, while keeping the well-being of Australians as the top priority," said CSIRO in a statement.
According to CSIRO chief executive, Dr Larry Marshall, as AI is increasingly used in homes, workplaces and communities, Australia must ensure it transforms industries and creates new jobs in the right way.
“As Australia’s national science agency, a focus on ethics, social licence to operate, and clear national benefit have always determined how we apply science and technology to solve Australia’s greatest challenges,” said Dr Marshall.
“The draft framework contextualises these age-old ethical considerations in the light of new technology, so everyone can have a say in inventing the future we need so our children can keep pace with emerging technologies like AI.”
Adrian Turner, CEO at CSIRO’s Data61, said AI is already here and developing quickly.
“AI represents a powerful general purpose technology that will help Australia solve some of our biggest problems relating to energy, health, ageing, safety, security, climate and the environment.”
“However, we will only realise this potential if we address underlying science and technology challenges in AI itself as well as its implications for people.
"Because of the deep influence AI will have on us all, we need to ensure that these systems work for us and deliver benefits individually and collectively.
"The AI ethics framework identifies principles and tools for achieving this in practice,” said Mr Turner.
New Stories
-
Evinco Therapeutics launches to pioneer immune-based treatments for Alzheimer’s disease
December 4, 2025 - - Latest News -
LTR Pharma advances SPONTAN program with ethics approval for Phase 2 clinical trial
December 4, 2025 - - Latest News -
Melbourne scientists discover how electrical pulses could transform tissue and organ regeneration
December 4, 2025 - - Latest News -
Island Pharmaceuticals secures boost as directors and major shareholders exercise options
December 4, 2025 - - Latest News -
BCAL launches national registry to track real-world impact of BREASTESTplus
December 4, 2025 - - Latest News -
Noxopharm advances autoimmune candidate as first multiple-dose cohort clears safety review
December 4, 2025 - - Latest News -
Medtech pipeline accelerates as report showcases translation success of MTPConnect-backed innovators
December 4, 2025 - - Latest News